As PTEN is lost in approximately 40% of prostate cancers (Pourmand et al., 2007; Taylor et al., 2010), we chose to work towards developing a personalized therapeutic approach using PTEN-deficient prostate cancer to explore selective vulnerability as a consequence of Akt’s metabolic activity. This evidence concerns the gene PTEN and prostate cancer.